About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | PHA-739358 for Treatment of Hormone Refractory Prostate Cancer

PHA-739358 for Treatment of Hormone Refractory Prostate Cancer

NCT00766324·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Nerviano Medical Sciences

Age

18–any

Sex

MALE

Healthy volunteers

Not accepted

You may be eligible if

Metastatic hormone refractory prostate cancer progressing after docetaxel based therapy
Adequate bone marrow, liver and kidney function

You may not be if

More than one prior chemotherapy line
Uncontrolled hypertension
Brain or leptomeningeal disease
Myocardial infarction, severe/unstable angina, symptomatic congestive heart failure, cerebrovascular accident in the previous 6 months

The record

StatusCompleted

PhasePhase 2

Taking part118

StartedSep 2007

UpdatedMay 28, 2014

Conditions

Metastatic Hormone Refractory Prostate Cancer

Where1

Nerviano Medical Sciences. Clinical Research Dept.
Nerviano, Milano, Italy